Immunovant Stock Financials

IMVT -  USA Stock  

USD 8.72  0.50  5.42%

Understanding current and past Immunovant Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Immunovant's financial statements are interrelated, with each one affecting the others. For example, an increase in Immunovant's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Immunovant's financials over time to get the whole picture.
Please harness Immunovant fundamental data analysis to find out if markets are presently mispricing the company. We were able to interpolate and analyze data for twenty-two available reported financial drivers for Immunovant, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Immunovant financials, including its shares owned by institutions, cash per share, as well as the relationship between the Cash per Share and short ratio . Given that Immunovant has a cash and equivalents of 379 M, we strongly advise you to confirm Immunovant regular market performance to make sure the company can sustain itself down the road. Use Immunovant to protect your portfolios against small market fluctuations. The stock experiences a very speculative upward sentiment. Check odds of Immunovant to be traded at $8.28 in 90 days.

Immunovant Fundamentals 

With this module, you can analyze Immunovant financials for your investing period. You should be able to track the changes in Immunovant individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Immunovant is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Immunovant includes many different criteria found on its balance sheet. For example, investors should never minimize Immunovant's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Immunovant's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Immunovant.

Immunovant Cash

  Chance Of Financial Distress
Over 62
Immunovant has more than 62 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Immunovant stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Immunovant's official financial statements usually reflect Immunovant's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Immunovant. For example, before you start analyzing numbers published by Immunovant accountants, it's critical to develop an understanding of what Immunovant's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Immunovant's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunovant's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Immunovant's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunovant. Please utilize our Beneish M Score to check the likelihood of Immunovant's management to manipulate its earnings.

Immunovant Company Summary

Immunovant competes with Brickell Biotech. Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 68 people.
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
LocationNew York; U.S.A
Business Address320 West 37th
Phone917 580 3099
Related EntityIMVT
CurrencyUSD - US Dollar

Immunovant Key Financial Ratios

Generally speaking, Immunovant's financial ratios allow both analysts and investors to convert raw data from Immunovant's financial statements into concise, actionable information that can be used to evaluate the performance of Immunovant over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Immunovant reports annually and quarterly.

Immunovant Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Immunovant's current stock value. Our valuation model uses many indicators to compare Immunovant value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunovant competition to find correlations between indicators driving Immunovant's intrinsic value. More Info.
Immunovant is currently regarded as number one stock in cash and equivalents category among related companies. It is considered the number one company in current valuation category among related companies reporting about  1.68  of Current Valuation per Cash and Equivalents. . Immunovant Cash and Equivalents is comparatively stable at the moment as compared to the past year. Immunovant reported Cash and Equivalents of 400.15 Million in 2020

Immunovant Systematic Risk

Immunovant's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Immunovant volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fifty-eight with a total number of output elements of three. The Beta measures systematic risk based on how returns on Immunovant correlated with the market. If Beta is less than 0 Immunovant generally moves in the opposite direction as compared to the market. If Immunovant Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Immunovant is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Immunovant is generally in the same direction as the market. If Beta > 1 Immunovant moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Immunovant Financials

What exactly are Immunovant Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Immunovant's income statement, its balance sheet, and the statement of cash flows. Potential Immunovant investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Immunovant investors may use each financial statement separately, they are all related. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunovant's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2010 2019 2020 2021 (projected)
Current Assets12.58 M109.08 M409.01 M441.3 M
Total Assets13.83 M109.39 M412.49 M445.05 M

Immunovant October 17, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Immunovant help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Immunovant. We use our internally-developed statistical techniques to arrive at the intrinsic value of Immunovant based on widely used predictive technical indicators. In general, we focus on analyzing Immunovant Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immunovant's daily price indicators and compare them against related drivers.
Information Ratio(0.029522)
Maximum Drawdown29.1
Value At Risk(5.54)
Potential Upside4.99
Please see Risk vs Return Analysis. Note that the Immunovant information on this page should be used as a complementary analysis to other Immunovant's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Immunovant Stock analysis

When running Immunovant price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEO Directory
Screen CEOs from public companies around the world
The market value of Immunovant is measured differently than its book value, which is the value of Immunovant that is recorded on the company's balance sheet. Investors also form their own opinion of Immunovant's value that differs from its market value or its book value, called intrinsic value, which is Immunovant's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunovant's market value can be influenced by many factors that don't directly affect Immunovant underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunovant's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunovant value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunovant's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.